Texas Permanent School Fund Corp Purchases 12,249 Shares of TransMedics Group, Inc. $TMDX

Texas Permanent School Fund Corp increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 124.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,118 shares of the company’s stock after purchasing an additional 12,249 shares during the period. Texas Permanent School Fund Corp owned 0.06% of TransMedics Group worth $2,964,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group during the 2nd quarter valued at $26,000. Smartleaf Asset Management LLC boosted its stake in TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after acquiring an additional 135 shares in the last quarter. Quarry LP grew its holdings in TransMedics Group by 88.5% in the first quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. Sound Income Strategies LLC bought a new position in shares of TransMedics Group during the second quarter valued at approximately $48,000. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of TransMedics Group during the second quarter valued at approximately $48,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Stifel Nicolaus started coverage on TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 price target on the stock. Piper Sandler dropped their target price on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Canaccord Genuity Group raised their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Stock Up 5.5%

TMDX stock opened at $127.67 on Friday. The stock has a market capitalization of $4.36 billion, a P/E ratio of 51.69 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $156.00. The business has a fifty day moving average price of $127.74 and a 200-day moving average price of $123.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same period last year, the company earned $0.12 EPS. TransMedics Group’s revenue for the quarter was up 32.2% on a year-over-year basis. Equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 13,062 shares of company stock valued at $1,797,634. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.